The FDA has approved a gene-editing therapy for sickle cell disease (SCD) for the first time.
The FDA has approved the first clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing therapy for use in patients with sickle cell disease (SCD). Exagamglogene autotemcel (exa-cel; Casgevy), developed by Vertex Pharmaceuticals in collaboration with CRISPR Therapeutics, is aimed at reducing or eliminating painful vaso-occlusive crises (VOCs) in patients with SCD.
“Sickle cell disease is a rare, debilitating and life-threatening blood disorder with significant unmet need, and we are excited to advance the field especially for individuals whose lives have been severely disrupted by the disease by approving 2 cell-based gene therapies today,” Nicole Verdun, MD, director of the Office of Therapeutic Products within the FDA’s Center for Biologics Evaluation and Research, said in a press release.1
This decision from the FDA comes after the committee accepted a biologics license application in June.2 The application contained data from trials evaluating exa-cel in patients with SCD and transfusion-dependent β-thalassemia (TDT). The treatment alters hematopoietic stem cells from a patient to produce more fetal hemoglobin F (HbF) in red blood cells. This increase in HbF could help to eliminate or reduce the amount of VOCs in patients with SCD, as well as reduce the transfusion requirements in patients with TDT.
Several trials are looking into the effectiveness of exa-cel in these populations. For example, CLIMB-111 and CLIMB-121 are ongoing phase 1/2/3 open-label trials evaluating the safety of exa-cel in patients aged 12 to 35 years and will continue into the CLIMB-131 long-term trial. Although the trials are still ongoing, results from the early stages of these trials had been presented at the European Hematology Association Congress in 2022.3
Included in the CLIMB-111, CLIMB-121, and CLIMB-131 trials were 75 patients, 44 of whom had TDT and 31 who had SCD. The follow-up ranged from 1.2 to 37.2 months. After exa-cel infusion, 42 of the 44 patients with TDT no longer needed transfusions after follow-up. The other 2 patients had 75% and 89% reductions in transfusions. HbF was also increased in patients with TDT after infusion, with an increase to more than 11 g/dL by the third month.
Similar results were found in patients with SCD in the same study, with all patients with SCD who had a mean of 3.9 VOCs per year having full elimination of VOCs after exa-cel infusion. HbF also made up about 40% of total Hb by month 4. The follow-up period for this was slightly different at 2.0 to 32.3 months. All results for patients with TDT and SCD were maintained after months 3 and 4, respectively.
In this study, serious adverse events were reported in 2 patients with TDT that were related to exa-cel. These included acute respiratory distress syndrome, headache, hemophagocytic lymphohistiocytosis, and idiopathic pneumonia syndrome in 1 patient; delayed neutrophil engraftment and thrombocytopenia were reported in the other patient. All adverse events were resolved.
The study that formed the basis of the FDA approval evaluated 31 patients with a history of at least 2 severe VOCs in the previous 2 years who had received exa-cel and had sufficient follow-up time of 24 months. The ongoing single-arm, multicenter study found that 93.5% of patients had achieved freedom from severe VOCs for at least 12 consecutive months. Engraftment was successful in all patients.
Low levels of platelets and white blood cells, abdominal pain, mouth sores, nausea, musculoskeletal pain, headache, vomiting, febrile neutropenia, and itching were among the other adverse events reported.
Simultaneous with the exa-cel approval, the FDA also approved a separate cell-based gene therapy, lovotibeglogene autotemcel (Lyfgenia), manufactured by bluebird bio, which uses a lentiviral vector to genetically modify the blood stem cells of patients with SCD to produce HbAT87Q, a form of hemoglobin that can reduce the risk of VOCs.1
References
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Reveals Link Between Ovarian Cancer, Subsequent Dry Eye Disease Incidence
May 13th 2024Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.
Read More
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More